Turning Pennies into dollars: (PINKSHEETS: LNGT), (OTCBB: LPTN.OB), (OTCBB: MVTG.OB).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://lngt.realpennies.com
MERCERVILLE, N.J., April 14 - (PINKSHEETS: LNGT) Laser Energetics, Inc. announced today that the Company has filed a patent application for a new BrightStar flashlamp pumped conductively air cooled Alexandrite laser technology. US Provisional Patent No. 61/026,281), filed with the US Patent and Trademark Office, encompasses a new type of Alexandrite laser technology.
Robert D. Battis, CEO of Laser Energetics, stated, "This technology advances the efficiency of the Alexandrite laser pump chamber, while simultaneously making it more reliable, easier to cool, and more compact. This new technological advancement removes around $3,000 from the cost to build of the laser pump chamber, and because of the improvement of operational efficiency, the cost of the power supply will decrease. This new laser technology will benefit LEI's - HyGeniLase, Inc. JV for its Dental Laser Application for cleaning teeth. In addition, this new laser technology will benefit LEI's planned collaborations with other medical laser companies using the technology for medical laser applications such as Hair Removal, Tattoo Removal and Photo Acoustic Imaging to name just a few."
This flashlamp pumped tunable BrightStar Alexandrite laser offers a more cost-effective solution than other laser technologies which are not wavelength tunable, like this new BrightStar Alexandrite laser. With a wall plug efficiency of 5%, this laser can be built one third the size of comparable technologies without water cooling. In addition because of its efficiency, it will run at 110 Volts, using around the same power as a hair dryer. "Better, Faster, Cheaper," says Battis. As a result, this new laser can serve more applications found in many areas of industry, science and the military as well. Like other Alexandrite lasers the company builds, the IR and UV light this laser emits can be transmitted into applications requiring beam transport through a fiber optic to a substrate or target.
"Our future patent will ensure our competitive edge in the marketplace for years to come," stated Battis. "The company is hard at work developing its new product line of lasers that are smaller and lighter, having a lower cost to build, providing LEI with the right technology to address an inexhaustible amount of laser applications, leading to increased sales and profits."
About Laser Energetics, Inc.: LEI has and continues to develop a comprehensive and strategic laser product line that addresses applications in Industry, Science, Medicine and the Military. The Company has had a primary focus on its Alexandrite laser technology. These tunable solid state lasers are unique in that they can be conductively air cooled to compete favorably against water cooled lasers in many applications. In addition, these lasers have one of the greatest wavelength tuning ranges with a bandwidth of over 250nm. The company is pursuing markets that are diverse yet can use the same laser with their compact user friendly design. This laser technology provides a sustainable advantage over many other lasers because of their tune-ability, conductively air cooled operation, and their efficiency allowing these lasers to operate at preferred lower voltages such as 110 Volts as well as the military standard 28 VDC, as compared to other less efficient competitive lasers that are large and need 220 Volts to operate.
For more info: http://lptn.realpennies.com
SAN DIEGO, CA-Apr 14, 2008 - (OTCBB: LPTN.OB) Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, has submitted an investigational new drug application to the U.S. Food and Drug Administration for iSONEP.
This drug candidate is the ocular formulation of sonepcizumab, a humanized monoclonal antibody against sphingosine-1-phosphate . The company expects to begin Phase 1 clinical trials of iSONEP as a treatment for age-related macular degeneration early in the third quarter of 2008.
Although Lpath will conduct its Phase 1 for iSONEP in "wet" AMD patients, the company considers iSONEP a potential treatment for a broad range of ocular diseases that extend well beyond wet AMD.
According to Roger A. Sabbadini, Lpath's founder and chief scientific officer, "Results of Lpath's ocular discovery program suggest that iSONEP may be a valuable therapeutic in the treatment of diabetic retinopathy, dry AMD, and uveitis, and in the prevention of scar formation associated with many glaucoma-related surgeries. These disorders, besides representing significant market potential, also represent significant unmet medical needs at the present time."
Scott R. Pancoast, Lpath's president and chief executive officer, added, "This IND is a significant achievement for our organization. Submission of the iSONEP IND package less than four months after the submission of the IND for our first drug candidate, ASONEP, underlines the strength of our drug discovery and development programs."
About iSONEP
iSONEP has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory, anti-vascular permeability, and anti-fibrosis. This combination of mechanisms suggests: iSONEP might have a comparative advantage over currently marketed products for the long-term maintenance of wet AMD; and iSONEP might demonstrate clinical efficacy in a broad range of retinal diseases where there is currently a significant unmet medical need, including diabetic retinopathy, dry AMD, uveitis, glaucoma-related surgery, and proliferative retinopathy.
About Lpath
Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP (the systemic formulation of sonepcizumab) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP (the ocular formulation of sonepcizumab), has demonstrated superior results in various preclinical AMD and retinopathy models. Lpath's third product candidate, Lpathomab, is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2 drug-discovery engine, which the company is using to add to its pipeline. For more information, visit www.Lpath.com.
For more info: http://mvtg.realpennies.com
Seattle, WA, April 14 - (OTCBB: MVTG.OB) Mantra Venture Group Ltd. announces that it will establish a research & development laboratory for its technology portfolio.
In March of 2008, Mantra acquired its flagship technology, a process for the Electrochemical Reduction of Carbon Dioxide , and is currently evaluating several other technologies for purchase. To ensure the rapid commercialization of its projects and the ongoing growth of its technology portfolio, Mantra is consolidating and expanding its research and testing activities in a new facility.
"We now have a sufficient number of projects in Mantra that it is desirable to have our own laboratory facilities to develop new products", said John Russell, Chair of Mantra's Scientific Advisory Board. "By collecting the various projects together, Mantra will have more control over their development and will be better positioned to recognize new opportunities arising from synergies between technologies, something that happens when skilled teams work together", Mr. Russell added.
Mantra has identified possible locations for the new facility in Vancouver, British Columbia and will be choosing a location in the coming months. Installation of the new facility will be overseen by Professor Colin Oloman, a member of Mantra's Scientific Advisory Board. Professor Oloman, who has over 40 years experience the field of chemical engineering, is professor emeritus of the University of British Columbia and faculty member at UBC's Clean Energy Research Center in Vancouver.
Said Mr. Larry Kristof, President and CEO of Mantra: "We have achieved a critical mass and it is time for us to establish an incubator for new products and a base from which to evaluate prospective technologies. The lab will also be the perfect setting to train field technicians as our projects mature and go to market."
The first technology to be developed at the lab will be Mantra's ERC process, invented by Professor Oloman and Dr. Hui Li. The technology is the first step in a planned closed-loop process to convert CO2 emissions into liquid fuel for fuel cells.
Mantra, through its group of sustainable energy, carbon reduction and consumer product subsidiaries, is set to enter the burgeoning green technology marketplace with an innovative, multi-faceted approach focused on profitability through sustainability. By aggressively seeking out new technologies and innovating solutions for a cleaner earth, Mantra intends to provide a highly profitable and, more importantly, socially and environmentally responsible investment for its shareholders.
Mantra is a public company quoted on the OTCBB under the symbol MVTG and the Frankfurt Stock Exchange under the symbol EDV 5MV
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment